| Quarter | Score |
|---|---|
| 2022-Q3 | 65.7 |
| 2022-Q4 | 49.4 |
| 2023-Q1 | 49.3 |
| 2023-Q2 | 36.1 |
| 2023-Q3 | 48.7 |
| 2023-Q4 | 43.0 |
| 2024-Q1 | 60.9 |
| 2024-Q2 | 60.6 |
| 2024-Q3 | 87.6 |
| 2024-Q4 | 86.2 |
| 2025-Q1 | 86.2 |
| 2025-Q2 | 70.6 |
| 2025-Q3 | 86.2 |
| 2025-Q4 | 86.2 |
| 2026-Q1 | 86.3 |
| 2026-Q2 | 86.4 |
Strong consensus, but price is extended — wait for pullback to funds' basis
Trading +43.3% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold TRMD. Avg conviction: 3.6%. Net holding. First tracked at $27.25 (current +43.3% vs tracked).
Oaktree Capital has 7.3% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Oaktree Capital | 7.3% | Reduce |
| Citadel Advisors | 0.0% | Add |